ABG Sundal Collier acted as sole global coordinator and bookrunner in Nanexa’s fully subscribed rights issue of approximately SEK 127 million

On Wednesday 7 July, Nanexa, the Swedish nanotechnology drug delivery company, announced the successful completion of a fully subscribed rights issue of approximately SEK 127 million. The rights issue was fully subscribed for through a combination of subscription commitments, subscription with and without subscription rights and guarantee commitments from the existing shareholder Rutger Arnhult via M2 Capital Management, and from external investors, including Health Runner and Modelio Equity.
In total, 25,347,813 new shares were issued at a subscription price of SEK 5.00 per share, resulting in proceeds of approximately SEK 127 million before transaction costs, which will be used to finance value-added activities in ongoing and planned clinical studies.